- Home
- Publications
- Publication Search
- Publication Details
Title
Landscape of Neoadjuvant Therapy for Breast Cancer
Authors
Keywords
Overall Survival, Tamoxifen, Trastuzumab, Lapatinib, Letrozole
Journal
ANNALS OF SURGICAL ONCOLOGY
Volume 22, Issue 5, Pages 1408-1415
Publisher
Springer Nature
Online
2015-03-01
DOI
10.1245/s10434-015-4405-7
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Impact of the Addition of Carboplatin and/or Bevacizumab to Neoadjuvant Once-per-Week Paclitaxel Followed by Dose-Dense Doxorubicin and Cyclophosphamide on Pathologic Complete Response Rates in Stage II to III Triple-Negative Breast Cancer: CALGB 40603 (Alliance)
- (2015) William M. Sikov et al. JOURNAL OF CLINICAL ONCOLOGY
- Abstract S1-03: Primary results from BETH, a phase 3 controlled study of adjuvant chemotherapy and trastuzumab ± bevacizumab in patients with HER2-positive, node-positive or high risk node-negative breast cancer
- (2014) DJ Slamon et al. CANCER RESEARCH
- TBCRC 008: Early Change in 18F-FDG Uptake on PET Predicts Response to Preoperative Systemic Therapy in Human Epidermal Growth Factor Receptor 2-Negative Primary Operable Breast Cancer
- (2014) R. M. Connolly et al. JOURNAL OF NUCLEAR MEDICINE
- Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
- (2014) Patricia Cortazar et al. LANCET
- Neoadjuvant and adjuvant trastuzumab in patients with HER2-positive locally advanced breast cancer (NOAH): follow-up of a randomised controlled superiority trial with a parallel HER2-negative cohort
- (2014) Luca Gianni et al. LANCET ONCOLOGY
- Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial
- (2014) Gunter von Minckwitz et al. LANCET ONCOLOGY
- Adjuvant Exemestane with Ovarian Suppression in Premenopausal Breast Cancer
- (2014) Olivia Pagani et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA)
- (2013) A. Schneeweiss et al. ANNALS OF ONCOLOGY
- Ki67 Measured after Neoadjuvant Chemotherapy for Primary Breast Cancer
- (2013) G. von Minckwitz et al. CLINICAL CANCER RESEARCH
- Exemestane Versus Anastrozole in Postmenopausal Women With Early Breast Cancer: NCIC CTG MA.27—A Randomized Controlled Phase III Trial
- (2013) Paul E. Goss et al. JOURNAL OF CLINICAL ONCOLOGY
- The 41st David A. Karnofsky Memorial Award Lecture: Academic Research Worldwide—Quo Vadis?
- (2013) Martine J. Piccart-Gebhart JOURNAL OF CLINICAL ONCOLOGY
- 18F-FDG PET/CT for Early Prediction of Response to Neoadjuvant Lapatinib, Trastuzumab, and Their Combination in HER2-Positive Breast Cancer: Results from Neo-ALTTO
- (2013) G. Gebhart et al. JOURNAL OF NUCLEAR MEDICINE
- Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study
- (2013) Sandra M Swain et al. LANCET ONCOLOGY
- Adjuvant bevacizumab-containing therapy in triple-negative breast cancer (BEATRICE): primary results of a randomised, phase 3 trial
- (2013) David Cameron et al. LANCET ONCOLOGY
- Fluorouracil, epirubicin, and cyclophosphamide (FEC-75) followed by paclitaxel plus trastuzumab versus paclitaxel plus trastuzumab followed by FEC-75 plus trastuzumab as neoadjuvant treatment for patients with HER2-positive breast cancer (Z1041): a randomised, controlled, phase 3 trial
- (2013) Aman U Buzdar et al. LANCET ONCOLOGY
- Definition and Impact of Pathologic Complete Response on Prognosis After Neoadjuvant Chemotherapy in Various Intrinsic Breast Cancer Subtypes
- (2012) Gunter von Minckwitz et al. JOURNAL OF CLINICAL ONCOLOGY
- Preoperative Chemotherapy Plus Trastuzumab, Lapatinib, or Both in Human Epidermal Growth Factor Receptor 2–Positive Operable Breast Cancer: Results of the Randomized Phase II CHER-LOB Study
- (2012) Valentina Guarneri et al. JOURNAL OF CLINICAL ONCOLOGY
- Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial
- (2012) José Baselga et al. LANCET
- Bevacizumab Added to Neoadjuvant Chemotherapy for Breast Cancer
- (2012) Harry D. Bear et al. NEW ENGLAND JOURNAL OF MEDICINE
- Neoadjuvant Chemotherapy and Bevacizumab for HER2-Negative Breast Cancer
- (2012) Gunter von Minckwitz et al. NEW ENGLAND JOURNAL OF MEDICINE
- Locally Advanced Breast Cancer: MR Imaging for Prediction of Response to Neoadjuvant Chemotherapy—Results from ACRIN 6657/I-SPY TRIAL
- (2012) Nola M. Hylton et al. RADIOLOGY
- Validation of a Novel Staging System for Disease-Specific Survival in Patients With Breast Cancer Treated With Neoadjuvant Chemotherapy
- (2011) Elizabeth A. Mittendorf et al. JOURNAL OF CLINICAL ONCOLOGY
- Randomized Phase II Neoadjuvant Comparison Between Letrozole, Anastrozole, and Exemestane for Postmenopausal Women With Estrogen Receptor–Rich Stage 2 to 3 Breast Cancer: Clinical and Biomarker Outcomes and Predictive Value of the Baseline PAM50-Based Intrinsic Subtype—ACOSOG Z1031
- (2011) Matthew J. Ellis et al. JOURNAL OF CLINICAL ONCOLOGY
- Four-Year Follow-Up of Trastuzumab Plus Adjuvant Chemotherapy for Operable Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: Joint Analysis of Data From NCCTG N9831 and NSABP B-31
- (2011) Edith A. Perez et al. JOURNAL OF CLINICAL ONCOLOGY
- Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial
- (2011) Luca Gianni et al. LANCET ONCOLOGY
- American Society of Clinical Oncology Clinical Practice Guideline: Update on Adjuvant Endocrine Therapy for Women With Hormone Receptor–Positive Breast Cancer
- (2010) Harold J. Burstein et al. JOURNAL OF CLINICAL ONCOLOGY
- Capecitabine in Addition to Anthracycline- and Taxane-Based Neoadjuvant Treatment in Patients With Primary Breast Cancer: Phase III GeparQuattro Study
- (2010) Gunter von Minckwitz et al. JOURNAL OF CLINICAL ONCOLOGY
- Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort
- (2010) Luca Gianni et al. LANCET
- A randomized trial exploring the biomarker effects of neoadjuvant sequential treatment with exemestane and anastrozole in post-menopausal women with hormone receptor-positive breast cancer
- (2009) O. C. Freedman et al. BREAST CANCER RESEARCH AND TREATMENT
- Meta-Analysis of Breast Cancer Outcomes in Adjuvant Trials of Aromatase Inhibitors Versus Tamoxifen
- (2009) Mitch Dowsett et al. JOURNAL OF CLINICAL ONCOLOGY
- Endocrine Therapy plus Zoledronic Acid in Premenopausal Breast Cancer
- (2009) Michael Gnant et al. NEW ENGLAND JOURNAL OF MEDICINE
- The prognostic significance of Ki67 before and after neoadjuvant chemotherapy in breast cancer
- (2008) Robin L. Jones et al. BREAST CANCER RESEARCH AND TREATMENT
- Letrozole Suppresses Plasma Estradiol and Estrone Sulphate More Completely Than Anastrozole in Postmenopausal Women With Breast Cancer
- (2008) J. Michael Dixon et al. JOURNAL OF CLINICAL ONCOLOGY
- Development of the 21-Gene Assay and Its Application in Clinical Practice and Clinical Trials
- (2008) Joseph A. Sparano et al. JOURNAL OF CLINICAL ONCOLOGY
- Preoperative Chemotherapy: Updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27
- (2008) Priya Rastogi et al. JOURNAL OF CLINICAL ONCOLOGY
- Outcome Prediction for Estrogen Receptor-Positive Breast Cancer Based on Postneoadjuvant Endocrine Therapy Tumor Characteristics
- (2008) M. J. Ellis et al. JNCI-Journal of the National Cancer Institute
- Intensified Neoadjuvant Chemotherapy in Early-Responding Breast Cancer: Phase III Randomized GeparTrio Study
- (2008) G. von Minckwitz et al. JNCI-Journal of the National Cancer Institute
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now